Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Twist Bioscience snapped up in vivo antibody discovery company Abveris Inc. in a deal valued at up to $190 million. The acquisition is expected to bolster Twist’s biopharma antibody capabilities.
Under the strategic collaboration, Neurocrine Biosciences and Sosei Group Corporation will develop and commercialize novel muscarinic receptor agonists to treat the said illnesses.
After indicating it might entertain a sale, Novartis may receive an offer from investment group EQT and the Struengmann family for its generic unit Sandoz.
News on COVID-19 vaccine developments and disease studies continue to deliver highs and lows. Here are some of the more recent happenings.
The FDA has granted Cambridge-based bluebird Bio a Priority Review of its Biologics License Application for betibeglogene autotemcel (beti-cel).
Connect Biopharma shares plummeted 55% despite reported positive topline data from its Phase II trial of CBP-201 for adults with moderate-to-severe atopic dermatitis.
CStone forged a licensing agreement with Jiangsu Hengrui Pharmaceuticals that grants the company access to a monoclonal antibody aimed at multiple forms of cancer.
This liquid biopsy uses a panel of peptide biosensors to analyze protein activity from a blood sample and provide actionable readouts of the disease state.
Switzerland-based Vifor Pharma is acquiring Spain’s Sanifit Therapeutics and another Swiss company, Inositec.
The beginning of booster vaccines for adults was in news for a long time. Well, CDS authorized it now, and here’s the reason behind the authorization.
“I hope to thread the needle between pricing responsibly and achieving profitability,” Jarrett said.
The U.S. Food and Drug Administration has a few PDUFA dates for the Thanksgiving Holiday week. Here’s a look.
PRESS RELEASES
Pharmaceutical service provider receives prestigious management award for the seventh year in a row · Family-owned company once again excels in all four key business areas · Site development and digitalization as strategic investment priorities · Focus on new sources for skilled workers and on lifelong learning
The upgraded platform offers a searchable database of over 300 risk-assessed HCPs, automated research scanning, and new flexible pricing options for mid-size drug developers.
New preprint by Jianghui Xiong, PhD, and the DeepoMe team introduces SteeraMed, a steerable biomedical world model for N-of-1 intervention reasoning across chronic diseases and aging